|Dr. Albert David Friesen Ph.D.||Founder, CEO & Chairman of the board||330.75k||N/A||1947|
|Dr. Neil Owens Ph.D.||Pres, COO & Interim CFO||166.67k||N/A||N/A|
|Dr. Reuben Saba Ph.D.||VP of Scientific & Medical Affairs||N/A||N/A||N/A|
|Ms. Jamie Gowryluk||VP of Commercial Operations||N/A||N/A||N/A|
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Medicure Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.